We were fortunate to attend the American Society of Hematology meeting earlier this month in San Diego. It brought together leading clinical scientists to present and discuss advances in malignant and non-malignant hematology.
Since the Cytobank platform is used by many who attended and presented, we were proud to see and be a small part of the exciting science. Highlights for us were:
- Remarkable success is being seen with CAR T cells in pediatric Acute Lymphoblastic Lymphoma (ALL)
However, there’s still a long way to go towards durable responses for most patients in most lymphomas and leukemias. Also, there’s a great need to better understand the biology behind troubling side effects including cytokine release syndrome and neurotoxicity. Which combination therapies will work best for which diseases? The race is on and the clinical trials process will need to adapt to keep pace with the pull from patients and physicians for these therapies.
- Strong interest in the continued development of and correlation between genomic and cellular data for applications.
This includes measuring and characterizing the in vivo proliferation and persistence of CAR T cells post infusion, which could correlate to patient response and Minimal Residual Disease detection (MRD) which is used to guide treatment. This is consistent with conversations with investigators at the meeting who are collecting and correlating single cell transcript and cytometry data.
Did you know: We are adding a .FCS to .CSV file converter to our platform early in the new year. If you are working to integrate genomic and proteomic data, we want to hear from you.
- Numerous posters and presentations featured Cytobank featured in infectious disease, immunological, and oncology applications
The most common application was analysis related to deep profiling of the tumor microenviroment. Some great examples include:
viSNE for cell subset ID was the most frequent algorithm used,
but we saw lots of SPADE, some CITRUS and combination use of SPADE on viSNE and also CITRUS being used to confirm results. It was exciting for us to see the use of multiple algorithms to make the most out of the data. We’ve included a few snapshots from the poster sessions showing other remarkable work that just so happened to feature some Cytobank analysis and visualizations.
It certainly seems like an exciting time to being working in the field of Hematology with the dramatic progress that is being made. At Cytobank we look forward to the continued collaborations and partnerships that drive the science and drive our platform forward to assist in the most complex cellular analyses.